Jump to Main Content

Meetings

Friday Satellite Symposia

The Friday Satellite Symposia (FSS) are industry-supported, CME-certified symposia that are offered the day preceding the American Society of Hematology (ASH) annual meeting. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.

The 2020 FSS will be a virtual experience taking place on Friday, December 4, 2020. The application period closed on June 15, 2020 at 11:59 p.m. PST. The FSS program will be available in August 2020.


Please review the official FSS guidelines to learn about hosting a symposium.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

For more information, contact Kelly Cade, ASH FSS Manager, Consultant, at fss@hematology.org.


  • A Case-based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis

    This program is supported by Mayo Clinic

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This program’s overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. Topics discussed will include choosing the right type of factor assays for monitoring newer factor and non-factor products for hemophilia management, optimal role of newer technologies like next generation sequencing for diagnosis of coagulation disorders, optimal laboratory evaluation of inherited platelet disorders, update on recent advances in the diagnosis of heparin induced thrombocytopenia and role of measuring direct acting oral anticoagulants.

    Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.

    Chairs:

    Rajiv K. Pruthi , M.B.B.S
    Mayo Clinic
    Rochester,  MN

    Dong Chen , M.D., Ph.D.
    Mayo Clinic
    Rochester,  MN

    Speakers:

    Ana I Casanegra , M.D.
    Mayo Clinic
    Rochester,  MN

    Dong Chen , M.D., Ph.D.
    Mayo Clinic
    Rochester,  MN

    Anand Padmanabhan , M.B.B.S., Ph.D.
    Mayo Clinic
    Rochester,  MN

    Rajiv K. Pruthi , M.B.B.S
    Mayo Clinic
    Rochester,  MN

    Heidi Zunker , Mayo Clinic
    Email: zunker.heidi@mayo.edu

    Registration:

    https://mayocliniclabs.com/2020mayosymp

    Acute Myeloid Leukemia: Using Available Evidence and Guidelines to Make Sense of a Rapidly Evolving Treatment Paradigm

    This program is supported by educational grants from Agios Pharmaceuticals Inc., Jazz Pharmaceuticals and Pfizer, Inc. Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This CME/CNE/CPE-certified webinar, developed by NCCN, will feature review of the latest clinical data, NCCN Guidelines updates, and management of different patient case studies. Renowned AML experts will provide their perspectives on recent changes in AML treatment and the rationale for the development of new and novel targeted treatment options that are individualizing the care of patients with AML. Engagement with the presenting faculty will be accomplished through technology that allows those attending to not only answer case and polling questions, but also directly submit questions and comments to the panel. In addition, the faculty will highlight available online resources along with the latest updates to the NCCN Guidelines to help provide practical insights to aid integration of new insights into practice after returning to the clinic after ASH.

    Chair:

    Farhad Ravandi , MBBS
    University of Texas- MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Amir T. Fathi
    Massachusetts General Hospital
    Boston,  MA

    Alice S. Mims , MD
    The Ohio State University Comprehensive Cancer Center
    Columbus,  OH

    Clinical Care Options , Clinical Care Options
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/AMLWinter2020NCCN

    Advances in Diagnosis and Management of Myelodysplastic Syndromes

    This program is supported by MDS Foundation, Inc.

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).

    Topics will include:

    Challenges in MDS Diagnosis

    Managing MDS in the Wake of a Global Pandemic

    Venetoclax in Higher-Risk MDS/AML

    Role of CAR-T Cells in Myeloid Malignancies:  Lessons Learned from Lymphoid Malignancies

    Targeted Therapies (enasidenib, ivosidenib, APR-246)

    Chair:

    Mario Cazzola , MD
    Fondazione IRCCS Policlinico San Matteo
    Pavia,  Italy

    Speakers:

    Rafael Bejar , MD, PhD
    University of California, San Diego
    La Jolla,  CA

    Jane E. Churpek , MD, MS
    University of Wisconsin School of Medicine and Public Health
    Madison,  WI

    Stephane De Botton
    Institut Gustave Roussy
    Villejuif,  France

    Amy E. DeZern , MD
    Johns Hopkins University School of Medicine
    Baltimore,  MD

    Saar I. Gill , MD, PhD
    University of Pennsylvania
    Philadelphia,  PA

    Katharina S. Götze
    Technical University of Munich
    Munich,  Germany

    Lea Harrison , MDS Foundation, Inc.
    Email: lharrison@mds-foundation.org

    Registration:

    https://www.mds-foundation.org/learning-center/2020-ash-registration/

    An Optimized Approach to Sickle Cell Disease Care in a New Era of Treatment

    This program is supported by Global Blood Therapeutics

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This continuing medical education symposium will address continuing and emerging educational needs in the care and management of patients with sickle cell disease (SCD). Experts in the field will provide didactic presentations and panel discussions to address persisting challenges in the management of SCD, the burden of disease, and provide guidance to integrate current and emerging management strategies into the clinic to enhance patient care and quality of life measures. Patient perspective videos will be utilized to further highlight the burden of SCD on mental health, quality of life, and its psychosocial impact. Current and emerging therapeutic options with the potential to limit disease burden and enhance quality of life will be evaluated for safety and efficacy to provide insight for their optimal integration into individualized treatment algorithms.

    Chair:

    Jane S. Hankins , MD, MS
    St. Jude Children's Research Hospital
    Memphis,  TN

    Speakers:

    Daniel E. Bauer , MD, PhD
    Boston Children’s Hospital
    Boston,  MA

    Modupe Idowu , MD
    University of Texas Health Science Center, McGovern Medical School
    Houston,  TX

    Caterina P. Minniti , MD
    Albert Einstein College of Medicine
    Bronx,  NY

    Akshay Sharma , MBBS
    St. Jude Children's Research Hospital
    Memphis,  TN

    CME Resource , Vindico Medical Education
    Email: CME@VindicoCME.com

    Registration:

    https://tallen.webcasts.com/starthere.jsp?ei=1364476&tp_key=48276e72b7

    Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy

    This program is supported by National Comprehensive Cancer Network

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This NCCN-developed webinar presents a great opportunity for clinicians to learn about the latest therapeutic advances in chronic lymphocytic leukemia (CLL). During the live event, the faculty will give a snapshot overview of advances in CLL including risk assessment, molecular profiling, along with current and emerging therapeutics. This overview will be followed by panel discussions of various patient case scenarios with expert recommendations and supporting clinical data. Ongoing clinical trials and promising agents and combinations currently under investigation will also be discussed. A moderated panel discussion and an audience question and answer session will close each section of the symposium and will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice. Participants will be able to fully interact and contribute to the cases discussed by the panel via the virtual platform. Throughout the webinar, participants will have the opportunity to directly query the faculty for further clarification of the education or to obtain expert perspective on their own treatment challenges. The webinar will also feature review and presentation of the latest updates to the NCCN guideline treatment algorithms to help guide practical application.

    Chair:

    William G. Wierda , MD, PhD
    University of Texas M.D. Anderson Cancer Center
    Houston,  TX

    Speakers:

    Jeremy S. Abramson , MD
    Massachusetts General Hospital Cancer Center
    Boston,  MA

    Brian T. Hill , MD
    Cleveland Clinic Foundation
    Cleveland,  OH

    Clinical Care Options , Clinical Care Options
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/CLLWinter2020NCCN

    Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Multiple Myeloma (Part 1 of a 4-Part Series)

    This program is supported by Abbvie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm, Oncopeptides, Sanofi Genzyme and Takeda Oncology

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This activity, the first of a 4-part live webinar series, will feature 5 multiple myeloma (MM) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions & scenarios related to the management of MM. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    Chair:

    Neil Love , MD
    Research To Practice
    Miami,  FL

    Speakers:

    Rafael Fonseca , MD
    Division of Hematology and Oncology, Mayo Clinic
    Scottsdale,  AZ

    Ola Landgren , MD, PhD
    Memorial Sloan-Kettering Cancer Center
    New York,  NY

    Nikhil C. Munshi , MD
    Dana-Farber Cancer Institute
    Boston,  MA

    Robert Z. Orlowski , MD,PhD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Edward A. Stadtmauer , MD, FACP
    Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
    Philadelphia,  PA

    Sylvia Eriksen , Research To Practice
    Email: seriksen@researchtopractice.com

    Registration:

    http://www.researchtopractice.com/Meetings/FSS2020

    Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

    This program is supported by Pfizer

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    Innovations in treatment options for acute lymphoblastic leukemia (ALL) has improved patient outcomes with the optimization of multi-agent chemotherapy regimens through the use of asparaginase compounds, and more recently, the validation of newer agent classes, such as tyrosine kinase inhibitors, antibody-drug conjugates, bispecific antibodies, and adoptive cell therapy agents, has also led to better outcomes and enhanced care.

    Looked at more closely, the development of antibody therapy in ALL and its integration into care can be considered a model for how to enhance standard treatment protocols over a range of settings, including induction/consolidation strategies prior to transplant, and as a way to induce deep, minimal residual disease-negative responses. In this PeerView “Tumor Board” symposium preceding the virtual 62nd ASH Annual Meeting and Exposition, leading hematology-oncology experts will discuss the most recent clinical evidence supporting modern antibody options in ALL, explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Register today for this important event!

    Chair:

    David I. Marks , MB, MS, FRACP, PhD, FRCPath
    Professor of Haematology and Stem Cell Transplantation
    Bristol,  United Kingdom

    Speakers:

    Daniel J. DeAngelo , MD, PhD
    Harvard Medical School Dana Farber Cancer Institute
    Boston,  MA

    Nicholas J. Short , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    PVI Live , PeerView Institute for Medical Education
    Email: Questions@PeerView.com

    Registration:

    www.PeerView.com/ALL-Live

    How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

    This program is supported by Actinium Pharmaceuticals, Gilead Sciences, Inc., and Jazz Pharmaceuticals, Inc.

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This activity has been developed in collaboration with The University of Texas MD Anderson Cancer Center.

    A wave of new science in acute myeloid leukemia (AML) has decisively ended the era of conventional cytarabine-based chemotherapy as the lone standard of care. This dramatic change was fueled by two developments: a greater understanding of AML biology and the various factors that define different AML subtypes and populations; and the rapid emergence and validation of multiple novel therapeutics across the disease spectrum. As a consequence, modern AML treatment protocols now include the use of novel cytotoxic formulations, epigenetic agents, targeted agents (FLT3, IDH1/2, and BCL-2 inhibitors), and novel antibodies, with therapeutic decisions based on a close clinical reading of baseline disease- and patient-related features.

     

    Led by a panel of expert clinicians this PeerView “How I Think, How I Treat” activity will explore the practice-changing evidence that has validated innovative approaches to managing high-risk AML (eg, secondary AML); the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout the scientific sessions, the experts will highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Join us for this exciting event and learn how leading clinicians have adapted their own practices when managing patients with AML.

    Chairs:

    Harry P. Erba , MD, PhD
    Duke University Medical Center
    Durham,  NC

    Naval Daver , MD
    The University of Texas, M.D. Anderson Cancer Center
    Houston,  TX

    Speakers:

    Tara Lin , MD
    University of Kansas Medical Center
    Westwood,  KS

    Gail J. Roboz , MD
    Weill Medical College of Cornell University New York-Presbyterian Hospital
    New York,  NY

    PVI Live , PeerView Institute for Medical Education
    Email: Questions@PeerView.com

    Registration:

    www.PeerView.com/AML20

    Managing Myeloma: Where We Are, Where We’re Going, and Where We SHOULD Be Going (Time to Choose Sides!)

    This program is supported by the Multiple Myeloma Research Foundation

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    In the last 17 years, clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. Perhaps even more remarkably, in this time 14 new drugs have been approved by the US Food and Drug Administration for use in MM—including eight new agents (panobinostat, ixazomib, elotuzumab, daratumumab, denosumab, selinexor, isatuximab, belantamab mafodotin) approved in the last 5 years alone. This expansion of treatment options brings both opportunities and challenges for oncology health care providers (HCPs). Indeed, the rapidity with which research data relating to MM diagnosis, monitoring, and therapy has matured and emerged to practice relevance ensures that MM management options will continue to expand and evolve.

    This symposium will follow a debate format and feature audience polling relating to the proffered arguments, as well as panel discussions.

    Chairs:

    Hearn Jay Cho , MD, PhD
    Multiple Myeloma Research Foundation
    Norwalk,  CT

    Paul G. Richardson , MD
    Dana-Farber Cancer Institute
    Boston,  MA

    A. Keith Stewart , MBChB
    Princess Margaret Cancer Centre, University Health Network
    Toronto,  ON, Canada

    Speakers:

    Adam D. Cohen , MD
    Perelman School of Medicine at the University of Pennsylvania
    Philadelphia,  PA

    Suzanne Lentzsch , MD, PhD
    Columbia University Medical Center
    New York,  NY

    David S. Siegel , MD
    Hackensack Univ. Med. Ctr.
    Hackensack,  NJ

    Karen Tenaglia , RedMedEd
    Email: ktenaglia@redmeded.com

    Registration:

    https://education.redmeded.com/a/QJCIKN

    Mapping the New Era in CLL Management: Precision Medicine, Optimized Therapeutic Sequencing, and Patient Perspectives in Treatment-Naïve and Relapsed Disease

    This program is supported by AstraZeneca LP, Adaptive Biotechnologies, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This accredited CE activity has been developed in collaboration with CLL Society Inc.

    The validation of innovative therapeutics for the treatment of chronic lymphocytic leukemia (CLL) has radically upended a decades-long consensus centered on chemotherapy-based treatment and provided clinicians and patients with a wide range of personalized treatment options. These highly active therapies, including BTK, PI3K, and BCL-2 inhibitors and next-generation antibodies, have opened the door to “uncharted medical territory,” where potent treatment, modern safety management strategies, and the potential for long-lasting, robust responses are redefining the approach to caring for CLL patients.

     

    This “Seminars and Tumor Board” live web broadcast will pair compelling, real-world case scenarios with the practice-changing evidence that continues to support the increasing role in treatment for novel therapeutics in CLL. This event will also explore the future of CLL care and illustrate how novel combinations and cellular therapy may lead to deep, durable, and minimal residual disease–negative responses. Throughout, our expert panel will describe the challenges and milestones of the patient’s journey in order to illustrate the human face of the dramatic progress made in managing CLL in recent years. Register now to join the experts for this unique activity and learn how innovation is fueling changes in treatment for CLL.

    Chair:

    John G. Gribben , MD, DSc, FRCP, FRCPath, FMedSci
    Queen Mary University of London
    London,  United Kingdom

    Speakers:

    Nicole Lamanna , MD
    Herbert Irving Comprehensive Cancer Center
    New York,  NY

    Alessandra Tedeschi , MD
    ASST Niguarda (Grande Ospedale Metropolitano Niguarda)
    Milano,  Italy

    Philip A. Thompson , MB, MS
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    PVI Live , PeerView Institute for Medical Education
    Email: Questions@PeerView.com

    Registration:

    www.PeerView.com/CLL-Live

    Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine

    This program is supported by Cleveland Clinic & AAMDS

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present the symposium, Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine. This CME-certified activity provides an in-depth and up-to-date review of research related to the management and treatment strategies for patients with MDS, AML, myeloproliferative neoplasms, and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

    Chair:

    Bhumika J. Patel , MD
    Cleveland Clinic
    Cleveland,  OH

    Speakers:

    Kelly L. Bolton , MD, PhD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Vikas Gupta , MD, FRCP, FRCPath
    Princess Margaret Cancer Centre, University Health Network
    Toronto,  ON, Canada

    Betty K. Hamilton , MD
    Cleveland Clinic Foundation
    Cleveland,  OH

    Jeffrey E. Lancet , MD
    H. Lee Moffitt Cancer Center & Research Institute
    Tampa,  FL

    Jaroslaw P. Maciejewski , MD, PhD
    Cleveland Clinic
    Cleveland,  OH

    Guillermo F Sanz , MD, PhD
    Hematology Department, Hospital Universitario y Politécnico La Fe
    Valencia,  Spain

    Samantha Pringle , Cleveland Clinic
    Email: pringls@ccf.org

    Registration:

    www.ccfcme.org/MDS2020

    Preparing for Personalized Care in MDS: Integrating Innovative Treatments Into a Cohesive Patient Care Model

    This program is supported by Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Taiho Oncology, Inc., and Takeda Oncology.

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This CE activity has been developed in collaboration with Aplastic Anemia and MDS International Foundation.

    Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterized by reduced and/or defective production of red blood cells, platelets, and mature granulocytes, often resulting in anemia, bleeding, increased risk of infection, and risk of transformation to AML. For many years, supportive therapy, blood transfusion, erythropoiesis-stimulating agents, and treatment of infections were the only therapies available. Subsequently, DNA methyltransferase inhibitors and immunomodulators showed survival benefits in MDS, leading to additional research on the efficacy of novel erythroid maturation agents in the setting of MDS-related anemia. Currently, multiple innovative therapies—including multikinase inhibitors, NEDD8-activating enzyme inhibitors, isocitrate dehydrogenase 1/2 inhibitors, BCL-2 inhibitors, and CD47 antibodies—are being investigated to improve care across different MDS populations, including low-, intermediate-, or high-risk patients, elderly individuals with comorbid conditions, and those ineligible for intensive treatment.

    In this CME web broadcast, an expert panel will discuss the diagnosis and management of MDS. The panelists will review innovative treatment strategies, prognostic scoring systems for risk stratification, and how hematologist-oncologists can recommend appropriate therapeutic options for patients with MDS.

    Chair:

    Steven D. Gore , MD
    National Cancer Institute
    Rockville,  MD

    Speakers:

    Prapti Patel , MD
    Harold C Simmons Comprehensive Cancer Center
    Dallas,  TX

    David A. Sallman , MD
    H. Lee Moffitt Cancer Center
    Tampa,  FL

    Michael R. Savona , MD
    Vanderbilt University Medical Center
    Nashville,  TN

    PVI Live , PeerView Institute for Medical Education
    Email: Questions@PeerView.com

    Registration:

    www.PeerView.com/MDS-Live

    Understanding Cold Agglutinin Disease: How Do Emerging Treatment Options Have the Potential to Transform Patient Outcomes?

    This program is supported by Sanofi Genzyme

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific Time

    This activity will bring together renowned experts in Cold Agglutinin Disease (CAD) treatment and clinical research together for an in-depth case-based discussion that will assess the clinical impact of recent and emerging trial data for CAD. A series of case presentations will be presented with clinical trial data tightly integrated to illuminate CAD treatment decisions related to patient and disease characteristics. Adverse events and management will be educationally tied to appropriate presentations. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care in the future. Faculty will be present onstage throughout the program. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.

    Chair:

    Alexander Röth , MD
    University of Duisburg-Essen
    Essen,  Germany

    Speakers:

    Wilma Barcellini
    Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan,  Italy

    David J. Kuter , MD
    Massachusetts General Hospital
    Boston,  MA

    Ilene C. Weitz
    University of Southern California
    Los Angeles,  CA

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/cad2020/meetings/cad2020satellite

  • Accelerating Toward a Cure for Myeloma: Emerging Data, New Agents, and an Evolving Treatment Paradigm

    This program is supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm & Oncopeptides. Provided by the Annenberg Center for Health Sciences at Eisenhower. In partnership with Clinical Care Options, LLC & the International Myeloma Foundation.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    Attendees of this annual International Myeloma Foundation/Clinical Care Options cosponsored program can expect to gain practical insights from a panel of experts as they discuss new therapeutic advances along with their personal approaches for myeloma care. This international panel will focus on evolving worldwide standards of care and will also provide their perspectives on promising agents that may soon change practice. As part of panel discussion, the experts will debate clinical questions, review available evidence and challenges that affect therapeutic decisions, and then share their individual treatment recommendations for each case. Throughout the program, learners will be able to vote on case scenarios and submit questions directly to the panel for their consideration. Discussion topics include:

    Case Discussion 1: Early Treatment for High-Risk Smoldering MM

    Case Discussion 2: Individualized Approaches to Frontline Treatment Selection

    Case Discussion 3: Managing the Patient With Relapsed Disease After = 1 Lines of Therapy

    Case Discussion 4: Understanding the Different Anti-BCMA Therapies

    Panel Discussion: Future Directions and a New 2021 Treatment Algorithm for MM

    Chair:

    Brian G.M. Durie , MD
    Cedars Sinai Cancer Center
    Los Angeles,  CA

    Speakers:

    Shaji K. Kumar , MD
    Mayo Clinic Rochester, Division of Hematology
    Rochester,  MN

    Thomas Martin , MD
    University of California
    San Francisco,  CA

    Philippe Moreau , MD
    Nantes University Hospital
    Nantes,  France

    S. Vincent Rajkumar , MD
    Mayo Clinic
    Rochester,  MN

    Jesús F. San-Miguel
    University of Navarra
    Pamplona,  Spain

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/MMWinter2020IMF

    Advances in GvHD: Expert Guidance on the Current Treatment Landscape, Optimizing Prophylaxis, and Integrating Novel Therapies

    This program is supported by an educational grant from Incyte Corporation. Provided by Clinical Care Options, LLC.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    During this webinar, learners can expect to receive review and panel discussion on advances/latest practice-changing data surrounding the most recent developments and emerging novel therapies for GvHD (including, but not limited to, the current treatment landscape, strategies in GvHD prophylaxis, and emerging therapies for patients with aGvHD and cGvHD). The selected format for this program features peer-to-peer discussion and direct expert faculty interaction with the audience. In addition, expert faculty will provide webinar attendees with a comprehensive understanding of practical approaches to patient management that will enhance their ability to integrate insights upon their return to the clinic. Each portion of the program will include a case review and didactic presentation by an expert faculty member followed by a moderated panel discussion and audience Q&A session. Faculty will discuss key clinical questions, available evidence, and challenges that affect clinical decisions as well as their individual management recommendations for each case. Throughout the program, learners will be able to vote on case scenarios and directly submit questions to the panel for their consideration. Discussion topics will include:

    • Updates in Diagnostic and Prognostic Biomarkers in GvHD
    • Optimizing Prophylaxis Strategies for GvHD
    • Recent Advances in aGvHD and cGvHD Therapy

    Chair:

    Corey S. Cutler , MD, MPH, FRCPC
    Dana-Farber Cancer Institute
    Boston,  MA

    Speakers:

    Nelson J. Chao , MD, MBA
    Duke University
    Durham,  NC

    David B. Miklos , MD, PhD
    Stanford University Medical Center
    Stanford,  CA

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/GVHDWinter2020

    Advances in Therapy for Inherited Non-Malignant Blood Disorders: Focus on Sickle Cell Disease and Hemophilia.

    This program is supported by an educational grant from Novo Nordisk Inc. This continuing medical education activity is provided by Vindico Medical Education.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    This continuing medical education symposium will address continuing and emerging educational needs in the care and management of patients with sickle cell disease or hemophilia. Experts in the field will provide didactic presentations and panel discussion on these rare non-malignant blood orders to address the tremendous burden of disease that occurs in these patients and provide guidance to integrate current and emerging management strategies into the clinic to enhance patient care and quality of life. The safety and efficacy of recent therapeutic advances will also be evaluated to provide insight into their integration into the treatment decision process and to ensure optimal, individualized patient care.

    Chair:

    Steven W. Pipe , MD
    University of Michigan
    Ann Arbor,  MI

    Speakers:

    Biree Andemariam , MD
    University of Connecticut
    Farmington,  CT

    Christine Guelcher , Hemostasis RN-BC, MS, PPCNP-BC
    Center for Cancer and Blood Disorders
    Washington,  DC

    Mark Reding , MD
    University of Minnesota Medical Center
    Minneapolis,  MN

    CME Resource , Vindico Medical Education
    Email: CME@VindicoCME.com

    Registration:

    https://tallen.webcasts.com/starthere.jsp?ei=1384337&tp_key=b5c283ac89

    Building New Management Models for NHL Care: A Seminar and Tumor Board on Innovative Chemo-sparing, Targeted, and Cellular Therapies in FL and DLBCL

    This program is supported by AstraZeneca LP, Adaptive Biotechnologies, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are two of the more common non-Hodgkin lymphomas (NHLs); these aggressive and indolent disorders represent the two classic “faces” of lymphoma. Recently, several novel therapeutic classes, including targeted agents, next-generation antibodies, and CAR-T cell therapy, have emerged as active strategies in diverse DLBCL and FL settings. These developments have challenged the use of standard immunochemotherapy-focused management and led to a new era of care in which increasingly, baseline factors can help identify patients who may benefit from the use of innovative therapeutics.

     

    This live web broadcast will provide learners with a clinical grounding on how new science is changing FL and DLBCL management. Each scientific seminar will open with a case-based “Tumor Board” session that will explore important factors in the selection and use of newer therapeutics, followed by a concise expert take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive NHL. Register today to learn how the experts are rising to the challenge of modern patient management for aggressive and indolent NHL. Don’t miss this informative event!

    Chair:

    Nathan H. Fowler , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Prof. Dr. Martin Dreyling , MD
    LMU Hospital
    Munich,  Germany

    Caron Jacobson , MD, MMSc
    Harvard Medical School
    Boston,  MA

    Krish Patel , MD
    Swedish Cancer Institute
    Seattle,  WA

    PVI Live , PeerView Institute for Medical Education
    Email: Questions@PeerView.com

    Registration:

    www.PeerView.com/NHL-Live

    Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies

    This program is supported by educational grants from Amgen and Dova Pharmaceuticals. Provided by Clinical Care Options, LLC.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    New science has driven innovative medical practice in the recognition and management of immune thrombocytopenia (ITP). This webinar will focus on practical guidance such as treatment goals, therapeutic strategies for initial and second-line treatment, and toxicity management as well as review the latest research progress on new therapeutic approaches for ITP. Each section of the webinar will include a case review and didactic presentation by an expert faculty member followed by a moderated panel discussion and audience Q&A session. Expert faculty will discuss key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as their personal treatment recommendations for each case. Throughout the webinar, learners will be able to vote on case scenarios and submit questions to the panel for their consideration. Discussion topics include:

    • Optimizing the Management of Newly Diagnosed ITP
    • Therapeutic Options for Patients With Previously Treated ITP
    • Caring for Special Populations of Patients With ITP

    Chair:

    David J. Kuter , MD
    Massachusetts General Hospital
    Boston,  MA

    Speakers:

    Keith R McCrae , MD
    Cleveland Clinic
    Cleveland,  OH

    Michael D Tarantino , MD
    Bleeding & Clotting Disorders Institute
    Peoria,  IL

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/ITPWinter2020

    Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)

    This program is supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    This activity, the second of a 4-part live webinar series, will feature 5 chronic lymphocytic leukemia (CLL) investigators serving as the faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of CLL. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    Chair:

    Neil Love , MD
    Research To Practice
    Miami,  FL

    Speakers:

    Matthew S. Davids , MD
    Harvard Medical School
    Boston,  MA

    Kerry A. Rogers , MD
    The Ohio State University
    Columbus,  OH

    Tanya Siddiqi , MD
    City of Hope Cancer Center
    Duarte,  CA

    Stephan Stilgenbauer , Professor Dr
    Saarland University Medical Center
    Homburg,  Germany

    William G. Wierda , MD, PhD
    University of Texas M.D. Anderson Cancer Center
    Houston,  TX

    Sylvia Eriksen , Research To Practice
    Email: seriksen@researchtopractice.com

    Registration:

    http://www.researchtopractice.com/Meetings/FSS2020

    D is for Diagnosis: Detecting and Treating Rare Disorders in Hematologic Practice

    This program is supported by Sanofi Genzyme

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    This program will discuss the latest data, share perspectives and best practices, and forecast applications of key clinical challenges and questions regarding identification of rare hematologic disorders and the importance of differential diagnosis when treating patients who present with hematologic symptoms of unknown origin. Attendees will be challenged to play the role of the detective as they approach each patient case to ultimately uncover the underlying disease at play. Audience members will be encouraged to look for ‘clues’ as they diagnose each patient, similar to how a detective would solve a case.  After solving each case, the faculty will present a comprehensive overview of available treatment options for each rare disease. The program is designed to take an investigational approach to treating rare hematologic diseases and will encourage interaction between faculty and audience.

    Chair:

    Atul Mehta , FRCP
    Royal Free Hospital
    London,  United Kingdom

    Speakers:

    Nicola Cooper
    Hammersmith Hospital, Imperial College London
    London,  United Kingdom

    Alan Lichtin, MD
    Leukemia Program
    Cleveland,  OH

    Marie Scully , MD
    University College London Hospitals, Cardiometabolic Program, National Institute for Health Research UCLH/UCL Biomedical Research Centre
    London,  United Kingdom

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Individualizing Treatment Plans and Optimizing Outcomes for Patients with MF and PV: Stories Behind The Science

    This program is supported by educational grants from Bristol Myers Squibb, Constellation Pharmaceuticals, Inc., Incyte Corporation, and PharmaEssentia USA.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and myelofibrosis (MF) are hematologic cancers that require careful monitoring and treatment. The goals for patients include reduction of symptom burden and prevention of progression. In recent years, the discovery of mutations in the JAK2 and CALR genes has enabled a paradigm shift toward individualized risk stratification and treatment.

    This live, educational webcast is designed to provide clinicians with the latest understanding of risk stratification and management of patients with PV and MF. This will include current and emerging use of targeted therapy and patient-specific adverse event management. These topics will be integrated into real-world case scenarios, where the panel of expert faculty will discuss best practices for managing MF and PV across the continuum of care. The overall goal of this program is to give participants the tools needed to make informed diagnostic and treatment decisions tailored to individual patients with MPNs.

    Chair:

    Srdan Verstovsek , MD, PhD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speaker:

    Dayna Kleinstein
    Physicians' Education Resource, LLC (PER)
    Cranbury,  NJ

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20mfpv/meetings/mfpv20ash

    MEDICAL CROSSFIRE®: BRIDGING UNMET NEEDS WITH EMERGING DATA IN RELAPSED/REFRACTORY DLBCL TO IMPROVE PATIENT OUTCOMES

    This program is supported by an educational grant from MorphoSys

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    Diffuse large B-cell lymphoma (DLBCL) is one of the most common forms of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of cases. The treatment landscape of DLBCL is evolving rapidly, particularly for patients with relapsed/refractory disease, with the recent addition of several new active agents to the armamentarium, and numerous other promising therapies in late-stage clinical development. Further, advances in understanding the underlying biology of DLBCL are resulting in more refined biomarker characterization for enhanced risk assessment and individualization of treatment. Clinicians must be aware of these changes and how to integrate them into their practices in order to optimize outcomes for their patients with DLBCL.

    This program will utilize PER®’s signature Medical Crossfire® format to highlight current and emerging standards of care in DLBCL. Five expert faculty will present recent and emerging data from key clinical trials, and engage in discussions of how current and investigational agents are changing treatment paradigms in DLBCL, with an emphasis on practical strategies for integrating new therapies in the clinic. New therapeutic approaches and clinical trial options will also be discussed. Participants will have the opportunity to engage in a live question-and-answer session with the faculty, to clarify information and address challenging scenarios in their own clinics.

    Chair:

    Gilles Salles , MD, PhD
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud
    Pierre Bénite,  France

    Speakers:

    Ranjana Advani , MD
    Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute
    Stanford,  CA

    Georg Lenz
    Full Professor, Director, Department of Hematology and Oncology, University Hospital Münster
    Munster,  Germany

    Kami J. Maddocks , MD
    Associate Professor of Clinical Internal Medicine, Lymphoma Program Director, Division of Hematology, Department of Internal Medicine, The Arthur G. James Cancer Hospital at The Ohio State University
    Columbus,  OH

    Grzegorz S. Nowakowski , MD
    Associate Professor of Medicine and Oncology, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic
    Rochester,  MN

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20dlbcl/meetings/dlbcl20ash

    Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult

    This program is supported by educational grants from Amgen, Jazz Pharmaceuticals, and Takeda Oncology

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    Numerous advances have been made in the diagnosis and management of adolescent and young adult (AYA) and adult patients with acute lymphoblastic leukemia (ALL). These include an improved understanding of ALL pathology, including cytogenetic and molecular abnormalities, and the development and incorporation of novel targeted and immune strategies into the field in recent years. Additionally, assessment of measurable/minimal residual disease (MRD) plays an increasing role in prognosis and treatment, and new MRD tests with increasing sensitivity are becoming available.

    To help hematologists/oncologists provide the best possible outcomes for their AYA and adult patients with ALL, this Medical Crossfire® will provide an open exchange of ideas and viewpoints. The program features a case-based agenda allowing participants to consider how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. This program will also address approaches to maximize the tolerability of current and emerging therapeutic approaches.

    Chair:

    Elias Jabbour , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Nicola Goekbuget , MD
    Head of Study Center Depart of Medicine II, Hematology/Oncology Goethe University Hospital
    Frankfurt,  Germany

    Hagop M. Kantarjian , MD
    Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Ching-Hon Pui , MD
    Member, St Jude Faculty, Chair, Oncology Department, Coleader, Hematological Malignancies Program, Director, China Region, St Jude Global, American Cancer Society Professor, Fahad Nassar Al-Rashid Chair of Leukemia Research, St Jude Children’s Research H
    Memphis,  TN

    Claire Roddie , PhD, MD
    Clinical Lead, CAR-T, University College London Hospitals Senior Lecturer in Haematology, University College London NHS Foundation Trust
    London,  United Kingdom

    Dayna Kleinstein , Physicians' Education Resource® (PER®)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20all/meetings/all20ash

    New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas

    This program is supported by Physicians' Education Resource, LLC

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. Theactivity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data across forms of NHL.  The activity is designed to highlight and test participants on the most clinically relevant data in NHL, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets. The faculty panel will convene to share their own practice preferences (“How I treat”), perspectives on the clinical trial data and share clinical pearls from their own practices.  To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.

    Chair:

    Sonali M. Smith , MD
    University of Chicago
    Chicago,  IL

    Speakers:

    Brad S. Kahl , MD
    Washington University School of Medicine in St. Louis
    Saint Louis,  MO

    Jason R. Westin , MD
    MD Anderson
    Houston,  TX

    Thomas E. Witzig , MD
    Mayo Clinic
    Rochester,  MN

    Dayna Kleinstein , Physicians' Education Resource, LLC
    Email: dkleinstein@gotoper.com

    Taking Action with Minimal Residual Disease: Technique, Role, and Utilization of MRD to Improve Outcomes in Patients with Hematologic Malignancies

    This program is supported by by educational grants from AbbVie Inc.; Adaptive Biotechnologies Corporation; and Amgen, Inc.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. The live activity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data for MRD monitoring and their implications for clinical practice.

    • The activity is designed to highlight and test participants on the most clinically relevant data in the use of MRD monitoring in hematologic malignancies, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
    • The faculty panel will convene in Medical Crossfire panel discussions to share their own practice preferences (“How I treat”), perspectives on the clinical trial data and share clinical pearls from their own practices.
    • To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.

    Chair:

    Andre H. Goy , MD
    John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack,  NJ

    Speakers:

    Nitin Jain , MD
    MD Anderson Cancer Center
    Houston,  TX

    Mark Roschewski , MD
    National Cancer Institute
    Bethesda,  MD

    Dayna Kleinstein , Physicians' Education Resource, LLC
    Email: dkleinstein@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20mrd/meetings/mrd20ash

    T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL

    This program is supported by educational grants from Seattle Genetics and Takeda Oncology

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    This activity will bring together renowned international experts in T-cell lymphoma treatment and clinical research in for an in-depth mock tumor board that will assess the clinical impact of recent and emerging trial data in PTCL and CTCL. A series of case presentations will be presented with clinical trial data tightly integrated to illuminate T-cell lymphoma diagnosis and treatment decisions related to front-line and beyond therapies, sequencing, switching and patient and disease characteristics. Adverse events and management will be educationally tied to appropriate presentations. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care in the future.

    Faculty will be present onstage throughout the program. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.

    The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting.

    Chair:

    Steven M. Horwitz , MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Speakers:

    Pamela B. Allen , MD,MSc
    Assistant Professor, Department of Hematology and Medical Oncology, Attending Physician, Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute
    Decatur,  GA

    Ahmet Dogan , MD, PhD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Neha Mehta-Shah , MD
    Washington University School of St. Louis
    St. Louis,  MO

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/tcltb20/meetings/tcltb20satellite

    The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets into Clinical Practice

    This program is supported by educational grants from Incyte Corporation, TG Therapeutics, Inc., and Verastem, Inc.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific Time

    This activity is intended to update clinicians with the latest information regarding the use of PI3K inhibitors in the treatment of hematologic malignancies, including chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, and other lymphomas. Throughout this activity, experts will review current and emerging data sets for PI3K inhibitors across hematologic malignancies, implications for clinical practice, and considerations for selecting a PI3K inhibitor for your patient. By participating in this activity, clinicians will be able to outline latest advances in PI3K inhibitors, evaluate the latest clinical data on efficacy and safety of current as well as emerging PI3K inhibitors, and make informed decisions about integrating these treatments, when approved, for best patient outcomes.

    Chair:

    John M. Pagel , MD, PhD, DSc
    Swedish Cancer Institute
    Seattle,  WA

    Speakers:

    Callie C. Coombs , MD
    University of North Carolina
    Chapel Hill,  NC

    Alexey Danilov , MD
    City of Hope Comprehensive Cancer Center
    Duarte,  CA

    Javier Pinilla Ibarz , MD, PhD
    H. Lee Moffitt Cancer Center & Research Institute
    Tampa,  FL

    Joanna M Rhodes , MD
    Northwell Health
    New Hyde Park,  NY

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20pi3k/meetings/pi3k20ash

  • A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care

    This program is supported by an educational grant from Bristol-Myers Squibb. Provided by Clinical Care Options, LLC.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    CAR T-cell therapy is at the leading edge of advances in the treatment of relapsed or chemotherapy-refractory leukemia, lymphoma, and myeloma. In this webinar, experts in these malignancies will use a case-based approach to examine current and future applications for CAR T-cell therapy, discussing key clinical data and providing their expert insights to maximize efficacy while appropriately managing toxicity. Throughout the webinar, attendees will interact with the experts using user-friendly technology. After each presentation, faculty will pause for a panel discussion and to answer questions from the audience. Discussion topics include:

    • CAR T-Cell Therapy in Lymphomas
    • CAR T-Cell Therapy for Myeloma
    • CAR T-Cell Therapies for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
    • Best Practices in Identifying and Managing CAR T-Cell–Mediated Toxicities

    Chair:

    Renier J. Brentjens , MD, PhD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Speakers:

    Frederick L. Locke , MD
    Moffitt Cancer Center
    Tampa,  FL

    Noopur S. Raje , MD
    Massachusetts General Hospital
    Boston,  MA

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/CARTWinter2020

    Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes

    This program is supported by educational grants from AstraZeneca and Beigene. Provided by Clinical Care Options, LLC.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    This CME-certified webinar will feature a review and discussion of patient case studies and key clinical trial data with renowned clinical experts providing their perspectives on recent advances with BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL). Along with the presenting faculty, attendees will be challenged to manage clinically relevant cases and will have multiple opportunities to directly interact with faculty in a dynamic question and answer format. Critical insights on the similarities and differences among multiple different BTK inhibitors will help prepare attendees to safely and effectively use these agents in their practice. In addition, the faculty will integrate results from CCO’s exclusive Interactive Decision Support Tools for CLL and BTK inhibitor adverse event management for all case discussions. Thousands of cases have been entered into these online decision tools to date, and data from this resource will be used to focus the content and cases discussed.

    Chair:

    Ian W. Flinn , MD, PhD
    Sarah Cannon Research Institute/Tennessee Oncology
    Nashville,  TN

    Speakers:

    Susan M. O'Brien , MD
    UCI Health
    Orange County, 

    John M. Pagel , MD, PhD
    Swedish Cancer Institute
    Seattle,  WA

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/CLLBTKWinter2020

    Adopting New Approaches for Relapsed/Refractory Follicular Lymphoma

    This program is supported by Epizyme, Inc. There may be additional supporters confirmed.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    Join us for Trivia Night! Compete against expert faculty and your peers through case-based challenges about relapsed/refractory follicular lymphoma. Test your skills selecting treatment and managing side effects as well as your knowledge of novel and emerging therapies. At the end of the symposium the participant who has the most points from correct responses will be recognized by the faculty panelists. This will be a lively symposium with panel discussion and clinical pearls.

    Chair:

    Loretta J. Nastoupil , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Connie Lee Batlevi , MD,PhD
    Memorial Sloan Kettering Cancer Center
    Short Hills,  NJ

    Matthew A. Lunning , DO, FACP
    University of Nebraska Medical Center
    Omaha,  NE

    Jaye Harden , MedscapeLIVE!
    Email: jharden@medscapelive.com

    Registration:

    www.medscape.org/sympo/follicular-lymphoma

    Advances in CAR T-Cell Therapy: What Does the Future Look Like?

    This program is supported by Kite Pharma, Inc. and Novartis Pharmaceuticals Corporation

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    The live portion of this curriculum will be presented as a (180) minute Friday Satellite Symposium proceeding the 62nd Annual ASH Meeting. Building upon highly successful past CAR-T Friday Satellite Symposia at the ASH Annual Meeting in 2016 and 2017, participants of this educational curriculum will be brought up to date on the most recent clinical advances and applications of CAR T-cell therapies and how this novel, emerging treatment paradigm will continue to impact treatment and management of patients with lymphoid malignancies. This symposium will bring together key clinical experts for an in-depth discussion on how to best apply the CAR T-cell therapy. The theme of this program will be a practical case-based approach that incorporates recent practice-changing trial data and places these findings in the context of real-world clinical situations that allows for clinical decision-making in multidisciplinary teams. A mix of didactic presentations, case studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

    Chair:

    David G. Maloney , MD, PhD
    Fred Hutchinson Cancer Research Center
    Seattle,  WA

    Speakers:

    Matthew J Frigault , MD, MSc
    Massachusetts General Hospital / Harvard Medical School
    Dorchester,  MA

    Stephanie Jackson , MSN, RN, AOCNS, BMTCN
    Ronald Reagan UCLA Medical Center
    Los Angeles,  CA

    Krishna V Komanduri , MD
    University of Miami Miller School of Medicine
    Miami,  FL

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20cart/meetings/cart20ash

    Applying Data to Practice: The Role of BTK Inhibitors for the Treatment of CLL

    This program is supported by AstraZeneca

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    Join us for this interactive, case-based, symposium where you can test your knowledge and skills using BTK inhibitors for the treatment of patients with treatment-naïve and relapsed/refractory CLL.  Using a tumor board approach, the panel will discuss real-world examples and will put the trial data for BTK inhibitors into clinical context. The audience will vote on treatment choices for patients and how they would manage treatment-related side effects.  The panel will discuss best practices for recognizing and mitigating side effects of BTK inhibitors. The symposium will also include future directions for BTK inhibitors, such as novel agents and investigational combinations.

    Chair:

    Jennifer Woyach , MD
    The Ohio State University, Wexner Medical Center
    Columbus,  OH

    Speakers:

    John N. Allan , MD
    Weill Cornell Medicine
    Long Island City,  NY

    Deborah M. Stephens , DO
    University of Utah/Huntsman Cancer Institute, Salt Lake City, UT
    Salt Lake City,  UT

    Jaye Harden , MedscapeLIVE!
    Email: jharden@medscapelive.com

    Registration:

    www.medscape.org/sympo/btk-cll

    Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Acute Myeloid Leukemia (Part 3 of a 4-Part Series)

    This program is supported by Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    This activity, the third of a 4-part live webinar series, will feature 5 acute myeloid leukemia (AML) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of AML. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    Chair:

    Neil Love , MD
    Research To Practice
    Miami,  FL

    Speakers:

    Mark Levis , MD, PhD
    Director, Adult Leukemia Program, Co-Division Director, Hematologic Malignancies, Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine
    Baltimore,  MD

    Alexander E. Perl , MD
    University of Pennsylvania
    Philadelphia,  PA

    Daniel A. Pollyea
    University of Colorado Denver
    Aurora,  CO

    Eytan M. Stein , MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Andrew H Wei , MBBS, PhD
    The Alfred Hospital
    Melbourne,  Australia

    Sylvia Eriksen , Research To Practice
    Email: seriksen@researchtopractice.com

    Registration:

    http://www.researchtopractice.com/Meetings/FSS2020

    Contemporary Management of Hemophilia A: Expert Guidance to Improve Patient Outcomes

    This program is supported by educational grants from Genentech, a member of the Roche Group, Sanofi Genzyme Corporation and Takeda Pharmaceutical Company Ltd. Provided by Clinical Care Options, LLC

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    During this webinar, learners will be provided with an overview of current individualized therapeutic approaches to manage patients with hemophilia A and a look ahead at new data and promising agents that may soon change practice. Renowned hemophilia experts will discuss the evidence behind current best practice management strategies for patients with hemophilia A, both with and without inhibitors, requiring prophylaxis. The program will include patient case challenges and reflection on considerations that affect therapeutic decisions. Recent clinical trial data and ongoing trials will be discussed, including emerging extended half-life (EHL) clotting factors, humanized bispecific antibody therapy, and novel therapeutic approaches with antithrombin inhibitors, anti-TFPI antibodies, and gene therapy. Learners will come away with an understanding of how these agents will affect management strategies for patients with hemophilia A in the current clinic and in the near future. Throughout the webinar, attendees will interact with experts through interactive case challenges and polling questions, as well as submitting questions directly to the panel for their consideration.

    Chair:

    Miguel A. Escobar , M.D.
    University of Texas Health Science Center
    Houston,  TX

    Speakers:

    Michael U. Callaghan , MD
    Central Michigan University
    Detroit,  MI

    Rebecca Kruse-Jarres , MD, MPH
    University of Washington
    Seattle,  WA

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/HemophiliaWinter2020

    Evolving the Standard of Care: Rethinking the Treatment Paradigm for Iron Deficiency Anemia

    This program is supported by Pharmacosmos Therapeutics, Inc.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    This engaging and interactive symposium led by experts in the field of iron deficiency anemia will provide learners with the most up-to-date information concerning treatment options for iron deficiency anemia and will present case-based strategies designed to improve clinicians' ability to diagnose and manage iron deficiency anemia in clinical practice.

    Chair:

    Carlo Brugnara , MD
    The Children's Hospital
    Boston,  MA

    Speakers:

    Michael Auerbach , MD
    Auerbach Hem-Onc Associates, Inc.
    Baltimore,  MD

    Myles Wolf , MD, MMsc
    Duke University School of Medicine
    Durham,  NC

    Jaye Harden , MedscapeLIVE!
    Email: jharden@medscapelive.com

    Registration:

    www.medscape.org/symposium/treating-iron-deficiency-anemia

    Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma

    This program is supported by GlaxoSmithKline, Janssen, Oncopeptides

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    Clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This live streamed educational symposium will involve 4 world renowned experts actively engaged in the management of patients with Multiple Myeloma.  Join us and listen to the experts debate the most pressing topics in MM. Polling questions, short didactic sessions, and Q&A opportunities will also be provided. Don’t forget to visit BioAscend.com to view an accredited videotaped discussion highlighting the most clinically relevant data presented which will be available 4 to 6 weeks after the symposium.

    Chair:

    Sagar Lonial , MD
    Winship Cancer Institute of Emory University
    Atlanta,  GA

    Speakers:

    Kenneth Anderson , MD
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
    Boston,  MA

    Pieter Sonneveld , MD, PhD
    Department of Hematology, Erasmus MC Cancer Institute
    Rotterdam,  Netherlands

    Peter Voorhees , MD
    Levine Cancer Institute, Atrium Health
    Charlotte,  NC

    Chloe Dunnam , Bio Ascend
    Email: dunnam@bioascend.com

    Registration:

    www.bioascend.com/MMDebate2020

    How to Do It™ Interactive Workshop: Taking Action With Clinical Advances in Chronic Lymphocytic Leukemia

    This program is supported by educational grants from AstraZeneca and Pharmacyclics.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    How to Do It™ Interactive Workshop: Taking Action With Clinical Advances in Chronic Lymphocytic Leukemia, a CME-certified Friday Satellite symposium to be presented at the ASH Annual Meeting will feature a series of didactic followed byHow To Do It  interactive small group breakouts between learners and faculty. Using a blended instructional model of didactic presentations, interactive panel discussions and small group breakouts is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues.

    • The activity is designed to highlight and test participants on the most clinically relevant data in CLL, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
    • To further enhance the integration of recent data into practice, the program will feature “How to Do It” group break outs, where presenting faculty and additional CLL faculty experts will join learners at their tables to share their own practice preferences (“How I treat”), perspectives on the clinical trial data and share clinical pearls from their own practices. Learners will have the opportunity to share cases for review with the faculty and other learners.

    Chair:

    Richard R. Furman , MD
    Weill Cornell Medical College
    New York,  NY

    Speakers:

    Farrukh T Awan , MD
    UT Southwestern
    Dallas,  TX

    Nicole Lamanna , MD
    Columbia University Medical Center
    New York,  NY

    John M. Pagel , MD, PhD, DSc
    Swedish Cancer Institute
    Seattle,  WA

    Dayna Kleinstein , Physicians' Education Resource, LLC
    Email: dkleinstein@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20cll/meetings/cll20ash

    Key Considerations: Advances in Gene Therapy for Hemophilia

    This program is supported by BioMarin, uniQure, Pfizer

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    As the science of gene therapy for hemophilia treatments continues to advance it is important that clinicians are prepared for implementation in their respective hemophilia treatment centers (HTCs). During this session faculty will deliver content in a variety of formats designed to engage the learners and increase retention of the information. This will include Concept Check-In, questions designed to allow learners to self-assess current understanding of gene therapy, faculty presentations during which expert faculty will review data presented in multimedia formats, as well as the use of case-based learning strategies and live interactive panel discussions.

    Chair:

    Glenn F. Pierce , MD,PhD
    World Federation of Hemophilia
    La Jolla,  CA

    Speakers:

    Lindsey George , MD
    The Children’s Hospital of Philadelphia
    Philadelphia,  PA

    Alfonso Iorio , MD, PhD
    McMaster University
    Hamilton,  ON, Canada

    Barbara A. Konkle , MD
    Washington Center for Bleeding Disorders
    Seattle,  WA

    Amanda Noe , The France Foundation
    Email: anoe@francefoundation.com

    Registration:

    https://www.eventbrite.com/e/key-considerations-advances-in-gene-therapy-for-hemophilia-registration-119438891941

    New Agents and Therapeutic Strategies in Beta-Thalassemia

    This program is supported by an educational grant from Bristol-Myers Squibb. Provided by Clinical Care Options, LLC.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    This webinar will reveal how experts approach current therapeutic decisions for their patients with ß-thalassemia and provide a look ahead at new data and promising agents that may change practice in the near future. Renowned ß-thalassemia experts will discuss the available evidence for both transfusion-dependent thalassemia (TDT) and non-TDT, including patient case presentations, their treatment recommendations for each case, and reflection on challenges that affect therapeutic decisions. Recent clinical trial evidence and ongoing clinical trials on novel therapeutic approaches, including erythroid maturation agents and gene therapy with lentiviral vectors, will be presented and discussed, with a focus how these agents may affect management strategies for patients with ß-thalassemia in the near future. Throughout the webinar, attendees will interact with the experts through interactive case-based challenges and polling questions. Finally, attendees will be able to submit questions directly to the panel for their consideration. Discussion topics include:

    • The Medical Need for Novel Therapies for ß-Thalassemia
    • Optimizing Current Management of ß-Thalassemia
    • Evolving Role of Biologic Therapies for ß-Thalassemia
    • The Promise of Gene Therapy in ß-Thalassemia

    Chair:

    Janet L. Kwiatkowski , MD, MSCE
    University of Pennsylvania Perelman School of Medicine
    Philadelphia,  PA

    Speakers:

    Jeanne Boudreaux , MD
    Children's Healthcare of Atlanta
    Atlanta,  GA

    Sujit Sheth , MD
    Weill Cornell Medicine
    New York,  NY

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/BetaThalWinter2020

    Sickle Cell Disease: Targeting Complications to Improve Long-term Implications

    This program is supported by an educational grant from Novartis Pharmaceuticals Corporation

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    Significant acute and chronic pain as well as increased infection risk resulting from hemolytic anemia and vaso-occlusion crisis (VOC) underlying sickle cell disease (SCD) greatly impacts morbidity and mortality. As such, there has been a call to action to develop therapeutics to address these symptoms and their underlying causes. As such, there has been novel therapy made available for patients in late 2019, about which it is vital that clinicians receive timely and relevant education.

    This activity is a virtual, interactive symposium that features a panel of expert faculty delivering clinically relevant, patient-centric information about the latest advances in sickle cell management. Focus will be placed on the implementation of practice strategies that align with current guidelines and emerging data. The activity will offer a state-of-the-art clinical update on management of SCD and related complications.

    Chair:

    Kenneth I. Ataga , MD
    UTHSC Center for Sickle Cell Disease
    Memphis,  TN

    Speaker:

    Dayna Kleinstein
    Physicians' Education Resource® (PER®)
    Plainsboro,  NJ

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20scd/meetings/scd20ash

    Transforming the Treatment Paradigm for Patients With MDS

    This program is supported by by educational grants from Bristol-Myers Squibb and Taiho Oncology. Provided by Clinical Care Options, LLC.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific Time

    New science has driven innovative medical practice in the management of myelodysplastic syndromes (MDS) with emerging efficacy and safety data on hypomethylating agents (HMAs), erythropoiesis-stimulating agents, immunosuppressants, and lenalidomide. This webinar will focus on evolving therapeutic standards, and expert faculty will provide practical insights for disease and supportive care management of MDS. Each section of the webinar will include a case review and didactic presentation by an expert faculty member, followed by a moderated panel discussion and audience Q&A session. Faculty will discuss key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the webinar, learners will be able to vote on case scenarios and submit questions to the panel for their consideration. Discussion topics will include:

    • Novel Therapeutic Approaches for the Treatment of MDS-Associated Anemia
    • Novel Therapeutic Approaches for the Treatment of MDS
    • Novel Therapeutic Approaches for the Treatment of Relapsed/Refractory MDS
    • Future Directions and Key Ongoing Clinical Trials

    Chair:

    Rami S. Komrokji , MD
    H. Lee Moffitt Cancer Center and Research Institute
    Tampa,  FL

    Speakers:

    Guillermo Garcia-Manero , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Jamile M. Shammo , MD
    Rush Univ. Med. Ctr.
    Chicago,  IL

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    Registration:

    www.clinicaloptions.com/MDSWinter2020

  • Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Hodgkin and Non-Hodgkin Lymphoma (Part 4 of a 4-Part Series)

    This program is supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics Inc and Seattle Genetics

    Friday, December 04, 2020
    7:00 p.m. - 10:00 p.m. Pacific Time

    This activity, the fourth of a 4-part live webinar series, will feature 5 lymphoma investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a pre-survey to ascertain their perspectives on controversial questions/scenarios related to the management of Hodgkin and NHL, including FL, mantle cell and DLBCL.  Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    Chair:

    Neil Love , MD
    Research To Practice
    Miami,  FL

    Speakers:

    Jonathan W. Friedberg , MD, MSSc
    James P. Wilmot Cancer Center
    Rochester,  NY

    John Kuruvilla , MD
    Princess Margaret Cancer Centre
    Toronto,  Canada

    Ann S. LaCasce , MD, MSc
    Dana-Farber Cancer Institute
    Boston,  MA

    John P. Leonard , MD
    Weill Cornell Medical College
    Pelham Manor,  NY

    Michael E. Williams , MD
    University of Virginia Health System
    Charlottesville,  VA

    Sylvia Eriksen , Research To Practice
    Email: seriksen@researchtopractice.com

    Registration:

    http://www.researchtopractice.com/Meetings/FSS2020

    Improving Outcomes in MDS and MPN: Tailoring Treatment Based on Patient- and Disease-Specific Factors

    This program is supported by educational grants from Agios Pharmaceuticals, Inc.; Astex Pharmaceuticals, Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Taiho Oncology, Inc.; and Takeda Oncology

    Friday, December 04, 2020
    7:00 p.m. - 10:00 p.m. Pacific Time

    This live program is designed to update physicians on the latest advancements in the clinical management of MDS and MPNs, including current approaches, diagnostic strategies, anemia management, and novel therapies under investigation for these diseases. In addition, this program will use case studies to apply recent findings to real-world case scenarios and will allow participants to reflect on how they might handle each scenario.

    Chair:

    Guillermo Garcia-Manero , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Ruben Mesa , MD
    UT Health San Antonio Cancer Center
    San Antonio,  TX

    Valeria Santini
    AOU Careggi-University of Florence
    Firenze,  Fi, Italy

    Ayalew Tefferi , MD
    Mayo Clinic
    Rochester,  MN

    Dayna Kleinstein , Physicians' Education Resource® (PER®)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20mdsmpn/meetings/mdsmpn20ash

    Leveraging Clinical Data and Trials to Inform Treatment for Patients with GvHD: An Expert Case-Based Discussion

    This program is supported by educational grants from Incyte Corporation and Kadmon Corporation, LLC

    Friday, December 04, 2020
    7:00 p.m. - 10:00 p.m. Pacific Time

    Leveraging Clinical Data and Trials to Inform Treatment for Patients With GvHD: An Expert Case Discussion will highlight recent advances in the treatment and prevention of acute and chronic graft-versus-host disease (GvHD). This program features expert faculty specializing in hematologic oncology and transplantation presenting the most recent clinical data of therapeutic agents in development, biomarkers for predicting risk, and the recognition and mitigation of treatment-related adverse events caused by GvHD treatments. This program is designed to be interactive through a combination of didactic presentations, challenging case studies, panel discussions, and a question-and-answer session to allow you the opportunity to hear from experts in the field regarding your most challenging clinical scenarios.

    Chair:

    James L. Ferrara , MD
    Pediatrics, Medicine, Hematology and Medical Oncology and Oncological Sciences The Icahn School of Medicine at Mount Sinai
    New York,  NY

    Speaker:

    Dayna Kleinstein
    Physicians' Education Resource® (PER®)
    Plainsboro,  NJ

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20gvhd/meetings/gvhd20ash

    State-of-the-Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches

    This program is supported by educational grants from Karyopharm Therapeutics Inc., Sanofi Genzyme, and Oncopeptides, Inc.

    Friday, December 04, 2020
    7:00 p.m. - 10:00 p.m. Pacific Time

    This program is designed to update physicians on the latest advancements in the clinical management of relapsed/refractory multiple myeloma, including novel agents under investigation, recently approved agents, and new combination approaches to treat this disease. In addition, this program will use case studies to apply recent findings to real-world case scenarios and will allow participants to reflect on how they might handle each scenario. Case-studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

    Chair:

    Maria-Victoria Mateos , MD, PhD
    University Hospital of Salamanca
    Salamanca,  Spain

    Speakers:

    Irene M. Ghobrial , MD
    Dana-Farber Cancer Institute
    Boston,  MA

    Thomas G. Martin III , MD
    University of California, San Francisco
    San Francisco,  CA

    Enrique M. Ocio , MD,PhD
    Hospital Universitario De Salamanca
    Santander,  Spain

    Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
    Email: info@gotoper.com

    Registration:

    https://www.gotoper.com/conferences/ash20rrmm/meetings/rrmm20ash